Guido Oelkers Announced His Departure as CEO of Sobi Effective Early 2027

Leadership Change at Sobi: Guido Oelkers to Step Down

In a significant move within the biotech sector, Guido Oelkers, the Chief Executive Officer of Swedish Orphan Biovitrum AB (commonly known as Sobi), has announced his intention to resign from his position. Oelkers, who has led the company for nearly a decade, will continue to fulfill his duties until the end of January 2027. This decision marks a pivotal moment for Sobi as it enters a new chapter in its growth strategy.

Transition Process Begins

The announcement came on August 3, 2026, as Oelkers informed the Board of Directors about his decision to step down. The company's board is set to commence the process of finding his successor, aiming for a seamless transition that would uphold the company's operational integrity and strategic vision. David Meek, the Chairman of Sobi's Board, expressed deep gratitude towards Oelkers for his nearly ten years of leadership, highlighting the substantial progress made under his guidance.

“I would like to sincerely thank Guido for his dedication and leadership at Sobi,” Meek stated. Under Oelkers’s stewardship, Sobi has not only strengthened its rare disease portfolio but also reported strong financial performance — achievements that position the company favorably for future growth.

Oelkers's Legacy

Reflecting on his time at Sobi, Oelkers remarked, “Leading Sobi has been a privilege.” His tenure has been marked by significant accomplishments including advancements in the company's pipeline, an expanded global footprint, and solidifying Sobi's status as a leader in the rare disease industry. His commitment to ensuring sustained growth for Sobi remains evident, as he pledged to work closely with the Board during the transition period.

Oelkers's resignation comes at a time when Sobi is well positioned to tackle future challenges and opportunities in the biopharma space. With approximately 2,000 employees worldwide, Sobi's operations in Europe, North America, the Middle East, Asia, and Australia contribute to its impressive revenue, which reached SEK 28 billion in 2025. The company’s stock is listed on Nasdaq Stockholm under the ticker STOSOBI.

Future Direction

While the leadership change represents a significant shift, Meek assured investors and employees that Sobi's current operations, strategic direction, and financial targets will remain unchanged during this transition. This reassurance is crucial as the company navigates its upcoming phases and continues its mission to deliver impactful therapies for patients with rare diseases.

In closing, Oelkers expressed confidence in the new leadership that will follow him, emphasizing the strong foundations set for the company's future. As Sobi prepares for the next chapter, the focus will remain on unlocking the potential of breakthrough innovations, ultimately transforming the lives of those who depend on them.

For more information about Sobi and its commitment to rare disease treatments, visit sobi.com.